Skip to main content
. Author manuscript; available in PMC: 2015 Aug 15.
Published in final edited form as: J Neuroimmunol. 2014 Jun 7;273(0):31–41. doi: 10.1016/j.jneuroim.2014.05.015

Figure 7. AS101 inhibits development of EAE.

Figure 7

Eight to ten week old female C57BL/6 mice were immunized with MOG (200μg) plus CFA and received PTX on the day of immunization and 48 hours later. 6 mice received 10μg AS101 (in 200μl volume) i.p. and 6 mice got vehicle PBS (200μl) beginning the day of immunization. The injections were repeated every other day. Mice were monitored daily for clinical disease. Experiments were terminated 34 days after immunization. The results showed that AS101 treatment ameliorates the development of EAE compared to PBS treated mice. Disease scores were for total 6 mice per group (Mean ± SEM). Results are representative of two independent experiments. *, p < 0.05 for AS101-treated versus vehicle PBS-treated mice.